Zusammenfassung
Infektionen im Zusammenhang mit schweren Neutropenien sind nach wie vor eine der Hauptursachen für Morbidität und Mortalität bei Patienten, die mit aggressiver Chemotherapie oder einer Transplantation hämatopoetischer Stammzellen behandelt wurden. Es liegt nahe, den Mangel an neutrophilen Granulozyten bei diesen Patienten durch eine Granulozytentransfusion beheben zu wollen. Die Einführung potenter Wachstumsfaktoren (G-CSF) und geeigneter Präparationstechniken ermöglicht heute die Bereitstellung funktionsfähiger Granulozyten in ausreichender Zahl, doch fehlen bislang überzeugende, randomisierte klinische Studien, die den klinischen Nutzen dieser Therapie belegen. Trotzdem haben erfolgversprechende kleinere Arbeiten das Interesse an dieser Therapieform wiederbelebt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Anderlini P, Champlin RE (2008) Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 111:1767–1772
Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, Rowley S, Przpiorka D, Champlin R (1997) Allogeneic blood stem cell transplantation: consideration for donors. Blood 90:903–908
Appelbaum FR, Bowles CA, Makuch RW, Deisseroth AB (1978) Granulocyte transfusion therapy of experimental pseudomonas septicemia: study of cell dose and collection technique. Blood 52:323–331
Burch JW, Mair DC, Meny GM, Moroff G, Ching SST, Naidoff MA, Steuer ER, Loftus SA, Armstrong J, Clemons TE, Klein BEK (2005) The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion 45:1701–1708
Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A (1996) Transfusion-related acute lung injury due to HLA-A2 antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol 93:707–713
Bux J, Cassens U, Dielschneider T, Duchscherer T, Edel E, Eichler H, Haas C, Moog R, Peschke H, Peters C, Ryzenkov I, Schlenke P, Ullrich H, Wiesneth M (2003) Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang 85:322–325
Cavallaro AM, Lilleby, K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI (2000) Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone marrow Transplant 25:85–89
Drewniak A, Boelens J-J, Vrielink H, Tool ATJ, Bruin MCA, van den Heuvel-Eibrink M, Ball L, van de Wetering D, Roos D, Kuijpers TW (2008) Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica 93:1058–1067
Dutcher JP, Schiffer CA, Johnston GS, Papenburg D, Daly PA, Aisner J, Wiernik PH (1983) Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection. Blood 62:354–360
Dutcher JP, Kendall J, Norris D, Schiffer CA, Aisner J, Wiernik PH (1989) Granulocyte transfusion therapy and amphotericin B: adverse reactions? Am J Hematol 31:102–108
Epstein RB, Chow HS (1981) An analysis of quantitative relationship of granulocyte transfusion therapy in canines. Transfusion 21:360–362
Freireich EJ, Morse EE, Bronson W, Carbone PP (1962) Transfusion of granulocytes from donors with chronic myelocytic leukemia to leukopenic recipients. J Clin Invest 41:1359
Ghodsi Z, Strauss RG (2001) Cataracts in neutrophil donors stimulated with adrenalcorticosteroids. Transfusion 41:1464–1468
Hubel K, Rodger E, Gaviria JM, Price TH, Dale DC, Liles WC (2005) Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion 45:1876–1889
Kerr JP, Liakopolou E, Brown J, Cornish JM, Fleming D, Massey E, Oakhill A, Pamphilon DA, Robinson SP, Totem A, Valencia Am, Marks DJ (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 123:114–118
Martin BA, Wright JL, Thommasen H, Hoog JC (1982) The effect of pulmonary blood flow on the exchange between the circulating and marginating pool of polymorphonuclear leucocytes (PMN) in dog lungs. J Clin Invest 69:1277–1285
Matthes G, Moog R, Radtke H, Wiesneth M, Zingsem J (2007) Durchführung präparativer Hämapheresen zur Gewinnung von Blutbestandteilkonzentraten – Empfehlungen zur präparativen Hämapherese der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI). Transfus Med Hemother 34:367–374
McCullough J, Weiblen BJ, Clay ME, Forstrom L (1981) Effect of leukocyte antibodies on the fate in vivo of indium-111-labeled granulocytes. Blood 58:164–170
Mishler JM, Hester JP, Huestis DW, Rock GA, Strauss RG (1983) Panel II: Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules. J Clin Apheresis 1:130–143
Morse EE, Freireich EJ, Carbone PP (1966) The transfusion of leukocytes from donors with chronic myelocytic leukemia to patients with leukopenia. Transfusion 6:183–192
Narvios AB, Pena E, Han XY, Lichtiger B (2002) Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. Blood 99:390–391
Narvios AB, Reddy V, Lichtiger B (2006) Method of removing incompatible red blood cells from granulocyte components. Transfus Apher Sci 35:179–180
Neppert J (1983) Die Granulozytentransfusion. Dtsch Med Wochenschr 108:3–5
Neppert J, Busch H (1979) Niedrige Leukozytenzahl bei Blutspendern. Münchener Med Wochenschr 121:1573–1574
Pegels JG, Bruynes ECE, Engelfriet CP, von dem Borne AEGKr (1982) Serological studies on platelet and granulocyte-substitution therapy. Br J Haematol 52:59–68
Peters A M (1998) Just how big is the pulmonary granulocyte pool? Clin Sci (Lond) 94:7–19
Price TH (2007) Granulocyte transfusion: current status. Semin Hematol 44:15–23
Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, Dale DC (2000) Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of infections in hematopoietic stem cell transplantation. Blood 95:3302–3309
Popovsky MA, Abel MD, Moore SB (1983) Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 128:185–189
Quillen K, Byrne P, Ying Yau Y, Leitman SF (2009) Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion 49:513–518
Roilides E, Walsh TJ, Pizzo PA, Rubin M (1991) Granulocyte Colony Stimulating Factor Enhances the Phagocytic and Bactericidal Activity of Normal and Defective Human Neutrophils. J Infect Dis 163:579–583
Rosenshein MS, Farewell VT, Price TH (1980) The cost effectiveness of therapeutic and prophylactic leukocyte transfusion. N Engl J Med 305:597–603
Sachs UJ, Bux J (2003) TRALI after the transfusion of cross-match-positive granulocytes. Transfusion 43:1683–1686
Shi J, Gilbert GE, Kokubo Y, Ohashi T (2001) Role of liver in regulating numbers of circulating neutrophils. Blood 98:1226–1230
Sulis ML, van de Ven C, Henderson T, Anderson L, Cairo MS (2002) Liposomal amphotericin B (Ambisome) compared with amphotericin B ± FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor /dexamethasone-mobilized allogeneic donor neutrophils. Blood 99:384–386
Strauss RG (1993) Therapeutic granulocyte transfusions in 1993. Blood 81:1675–1678
Strauss RG, Connett JE, Gale RP, Bloomfield CD, Herzig GP, McCullough J, Maguire LC, Winston DJ, Ho W, Stump DC, Miller WV, Koepke JA (1981) A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 305:597–603
Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman S (1996) Alloimmunization after granulocyte transfusions. Transfusion 36:1009–1015
Stroncek DF, Yai YY, Oblitas J, Leitman SF (2001) Administration of G-CSF plus dexamethasone produces greater granulocyte yields while causing no more donor toxicity than G-CSF alone. Transfusion 41:1037–1044
Vamvakas C, Pineda AA (1996) Meta-Analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis 11:1–9
Vamvakas C, Pineda AA (1997) Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 12:74–81
Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB (1981) Lethal pulmonary reactions associated with the combined use of Amphotericin B and leukocyte transfusions. N Engl J Med 304:1185–1189
Yomtovian R, Abramson J, Quie P, McCullough J (1981) Granulocyte transfusion therapy in chronic granulomatous disease. Report of a patient and review of the literature. Transfusion 21:739–743
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bux, J., Sachs, U. (2010). Therapie mit Granulozyten. In: Kiefel, V., Mueller-Eckhardt, C. (eds) Transfusionsmedizin und Immunhämatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12765-6_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-12765-6_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12764-9
Online ISBN: 978-3-642-12765-6
eBook Packages: Medicine (German Language)